James P. Allison Institute at MD Anderson seeks to refocus immunotherapy research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

James Allison has reshaped cancer drug development, making checkpoint inhibitors a staple of therapy in many key indications—and dramatically improving survival outcomes in previously recalcitrant diseases.

Allison shared the 2018 Nobel Prize in Physiology or Medicine for his fundamental discoveries in T cell biology and his invention of ipilimumab, the first immune checkpoint inhibitor to treat cancer (The Cancer Letter, Oct. 5, 2018). 

This innovation was so important that it has taken on a life of its own, spawning hundreds of trials, often of “me-too” compounds advanced by drug manufacturers vying to get duplicative versions of checkpoint inhibitors in efforts to gain a foothold in the immunotherapy market.

Now, Allison and colleagues at MD Anderson Cancer Center are trying to focus the scientific agenda, tackling the fundamental questions—starting with why do some patients benefit while others do not—and conducting studies that would result in expansion of knowledge about this class of drugs.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Matthew Bin Han Ong
Matthew Bin Han Ong
Paul Goldberg
Editor & Publisher
Table of Contents

YOU MAY BE INTERESTED IN

MAIA Biotechnology Inc. and BeiGene entered into a clinical supply agreement to assess the efficacy of THIO, MAIA Biotechnology’s small molecule telomere-targeting anticancer agent, in combination with BeiGene’s immune checkpoint inhibitor tislelizumab, in three cancer indications. The single-arm pivotal phase II trials will study the drug combination in hepatocellular carcinoma, small cell lung cancer, and colorectal cancer.

In a new article on the Cancer History Project, the American Cancer Society profiles three ACS-funded Nobel laureates:  David Baker, PhD2024 Nobel PrizeChemistry Victor Ambrose, PhD 2024 Nobel Prize Physiology or Medicine Gary Ruvkun, PhD2024 Nobel Prize Physiology or Medicine They join a cohort of 50 other ACS-funded Nobel laureates.  “The American Cancer Society’s legacy, with 53 Nobel...

Matthew Bin Han Ong
Matthew Bin Han Ong
Paul Goldberg
Editor & Publisher

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login